Skip Navigation


JAC Advance Access originally published online on January 24, 2008
Journal of Antimicrobial Chemotherapy 2008 61(4):798-804; doi:10.1093/jac/dkn015
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
61/4/798    most recent
dkn015v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Xu, Y.
Right arrow Articles by Li, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, Y.
Right arrow Articles by Li, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations

Yonghao Xu, Lamei Chen and Chunyang Li*

Department of Dermatology, Qilu Hospital, Shandong University, Ji’nan 250012, China

Received 1 October 2007; returned 23 October 2007; revised 18 November 2007; accepted 31 December 2007

* Corresponding author. Tel: +86-53182169390; Fax: +86-53186927544; E-mail: drlichunyang{at}hotmail.com

Objectives: To investigate fluconazole susceptibility of Candida albicans from non-AIDS patients and to analyse the relationship between mutations in the ERG11 gene of these isolates and fluconazole resistance.

Methods: Four hundred and twenty-six clinical isolates of Candida species were collected. Fluconazole susceptibility was tested in vitro using microdilution and disc diffusion assays. The ERG11 genes of 23 isolates of C. albicans (8 susceptible and 15 resistant) and 6 type strains (4 susceptible and 2 resistant) were amplified in three overlapping regions of the gene and sequenced.

Results: Of the 426 isolates collected, 68.6% were C. albicans; however, only 5.1% were resistant to fluconazole. Eighteen silent mutations and 19 missense mutations were detected. There were six missense mutations only in resistant isolates or resistant type strains: (i) G487T (A114S) and T916C (Y257H) appeared simultaneously in 14 fluconazole-resistant isolates without any other mutation; these may be associated with resistance; (ii) T541C (Y132H) and T1559C (I471T) are known to contribute to fluconazole resistance; and (iii) C1567A (Q474K) or a novel mutation T1493A (F449Y) was identified but correlations with resistance have not been studied.

Conclusions: In this survey, C. albicans is the major cause of candidiasis in non-AIDS patients, and some isolates that are resistant to fluconazole have G487T and T916C mutations in ERG11 that are associated with fluconazole resistance.

Keywords: C. albicans , drug susceptibility testing , lanosterol 14{alpha}-demethylase


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.